<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03358004</url>
  </required_header>
  <id_info>
    <org_study_id>IRFMN-BRC-6992</org_study_id>
    <nct_id>NCT03358004</nct_id>
  </id_info>
  <brief_title>the Role of Two Different Metronomic Chemotherapy Regimens in Locally Advanced or Metastatic Triple Negative Breast Cancer Patients (TNBC) as Maintenance Therapy After First Line Treatment</brief_title>
  <acronym>VICTOR3</acronym>
  <official_title>An International, Multicenter, Phase II, Randomized, Parallel-arm Trial Investigating the Role of Two Different Metronomic Chemotherapy Regimens in Locally Advanced or Metastatic Triple Negative Breast Cancer Patients (TNBC) as Maintenance Therapy After First Line Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mario Negri Institute for Pharmacological Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mario Negri Institute for Pharmacological Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      TNBC, defined by the lack of immunohistochemical staining for oestrogen receptors,
      progesterone receptors, and lack of overexpression or amplification of HER2/neu, has an
      aggressive biological behaviour, marked by increased risk of recurrence and poorer survival
      compared with hormone receptor-positive subtypes.

      The key points for the rationale of the present study are:

        1. Despite different efforts for improving the outcome of TNBC patients, the median
           distant-disease free interval for relapsed triple-negative breast cancer is about 1-2
           years, and the median survival for metastatic TNBC is approximately one year.

        2. International guidelines currently recommend polychemotherapy instead of sequential
           single agents as first-line treatment in this subgroup of patients, but no data is
           available at the moment regarding the optimal duration of chemotherapy.

        3. There is growing evidence to suggest that platinum-based therapy may have a role in both
           advanced and early-stage TNBC, though results are not definitive. Three randomized phase
           II neoadjuvant trials have been reported, two of which demonstrated an improvement in
           pathological complete response (pCR) rates when carboplatin is added to anthracycline
           and taxane-based chemotherapy, though this pCR improvement came at the cost of an
           increase in toxicity. Definitive results from phase III trials demonstrating improvement
           in long-term outcomes such as event-free and overall survival are not yet available, and
           it remains unclear how to optimally incorporate platinums into neoadjuvant therapy, as
           toxicity is enhanced when platinum is incorporated as an add-on to standard combination
           chemotherapy backbones. A randomized phase III trial comparing cisplatin plus
           gemcitabine to paclitaxel plus gemcitabine has been published recently. After a median
           follow-up of 16.3 months in the cisplatin plus gemcitabine group and 15.9 months in the
           paclitaxel plus gemcitabine group, the hazard ratio for progression-free survival was
           0.692 (95% CI 0•523-0•915; pnon-inferiority&lt;0•0001, superiority=0•009. Thus cisplatin
           plus gemcitabine was both non-inferior to and superior to paclitaxel plus gemcitabine.
           Median progression-free survival was 7.7 months (95% CI 6.2-9.3) in the cisplatin plus
           gemcitabine group and 6.5 months (5.8-7.2) in the paclitaxel plus gemcitabine group.

        4. In both early and advanced disease settings, response rates appear to be influenced by
           germ line BRCA1 and BRCA2 mutation status, and BRCA1 and BRCA2 mutation status has
           emerged as an important potential biomarker for platinum therapy. Outside of the BRCA
           mutant setting, there is certainly good reason to believe that there are patients with
           sporadic TNBC who stand to benefit greatly from a platinum-based approach. Tumour-based
           assays that detect levels of genomic scarring caused by the accumulation of DNA damage
           over time secondary to underlying DNA repair defects, such as the Myriad HRD assay, have
           potential to identify non carriers of BRCA1 or BRCA2 mutations with &quot;BRCA-like&quot; breast
           cancer, who may respond to DNA repair- targeted treatment strategies, such as platinum
           agents.

      One of the most promising way to improve clinical outcome in poor-risk patients is
      represented by maintenance therapy with a non-cross resistant regimen after an induction
      treatment, until disease progression. Nevertheless, the main limit to such a strategy is the
      choice of chemotherapy agents, considering that patients could be treated for a long period
      of time The results of the VICTOR-1 study was recently published, the aim of this study was
      the determination of the maximum tolerated dose of oral metronomic schedule of vinorelbine
      (VNR) in combination with fixed doses of capecitabine (CAPE), as well as to confirm the
      safety profile of the combination in a cohort of HER2-negative metastatic breast cancer
      patients. The results demonstrated a lower incidence of hematological grade 3-4 adverse
      events (1.1%), in comparison to what published in other series, using the standard schedules
      of the two drugs. The present study is designed to select the best arm between oral
      metronomic schedule of vinorelbine (VNR) and combination of oral metronomic schedule VNR with
      fixed doses of capecitabine (CAPE) as maintenance therapy in advanced TNBC patients
      responders after an induction treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 30, 2017</start_date>
  <completion_date type="Anticipated">September 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS-12 weeks</measure>
    <time_frame>At 12 weeks from the date of treatment start.</time_frame>
    <description>Progression free survival after 12 weeks of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>through study completion, an average of 3 years. OS, calculated for each patient as the time from the date of treatment start to the date of death.</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>through study completion, an average of 3 years. PFS calculated in each patient as the time from the date of treatment start to the date of first progression or death, whichever comes first.</time_frame>
    <description>Progression free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>through study completion, an average of 3 years</time_frame>
    <description>safety profile of each treatment Maximum toxicity grade experienced by each patient for each specific toxicity; frequency of patients experiencing AEs that are recorded as grade 3-5 (also grade 2 for neurotoxicity); according to NCICTC AE version 4.03</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Triple Negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>ARM A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vinorelbine 50 mg, thrice a week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vinorelbine 40 mg thrice a week + capecitabine 500 mg thrice a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine Tartrate</intervention_name>
    <description>Metronomic treatment with vinorelbine 50 mg (three times/week) until progression in ARM A</description>
    <arm_group_label>ARM A</arm_group_label>
    <arm_group_label>ARM B</arm_group_label>
    <other_name>Navelbine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine 500 MG</intervention_name>
    <description>Metronomic treatment with capecitabine 500 mg (three times/day) combined with vinorelbine 40 mg (three times/week) with until progression</description>
    <arm_group_label>ARM B</arm_group_label>
    <other_name>Capecitabine Mylan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female, aged ≥ 18 years old;

          -  Eastern Cooperative Oncology Group performance status (ECOG -PS) ≤ 1;

          -  Locally advanced or metastatic triple-negative breast cancer, i.e. HER2-negative
             status and ER and PgR negative status (as per local assessment);

          -  Treatment with 1st line chemotherapy (with any drug excepted Bevacizumab-based
             regimens) as per clinical practice, and non-progressive when the treatment was
             terminated;

          -  No more than 6 cycles of the previous chemotherapy;

          -  At least one measurable lesion according to Response Evaluation Criteria in Solid
             Tumors (RECIST, version 1.1);

          -  Willingness and ability to comply with the study protocol as judged by the
             Investigator;

          -  For women who are not postmenopausal (i.e., &lt; 2 years after last menstruation) and who
             are sexually active: agreement to use an adequate method of contraception (oral
             contraceptives, intrauterine contraceptive device, barrier method of contraception in
             conjunction with spermicidal jelly) during the treatment period and for at least 6
             months after the last dose of study drug;

          -  Provision of a written informed consent signed prior to enrolment according to
             ICH/GCP.

        Exclusion Criteria:

          -  Previous treatment with vinorelbine or capecitabine;

          -  1st line therapy with a bevacizumab-based regimen;

          -  Presence of brain metastases;

          -  Any other investigational drug or any anti-cancer treatment (except for radiotherapy,
             if the treatment field does not include the liver);

          -  Inadequate bone marrow, hepatic or renal function including the following:

               1. absolute neutrophils count of &lt; 1.5 cells x 109/L, platelet count &lt; 100 cells x
                  109/L, or hemoglobin &lt; 8 g/L;

               2. serum total bilirubin &gt;1.5 × institution upper limit of normal [ULN], aspartate
                  aminotransferase and alanine aminotransferase &gt;2.5 × ULN, or &gt;5 × ULN for
                  patients with liver metastases, alkaline phosphatase &gt;2.5 × ULN, or &gt;5 × ULN for
                  patients with liver metastases, or &gt;10 × ULN for patients with bone metastases;

               3. serum creatinine concentration &gt;1.5 × ULN, creatinine clearance &lt;50 mL/min
                  calculated according to Cockcroft-Gault equation, and coagulation parameters
                  international normalized ratio &gt;1.5;

          -  With the exception of basal cell carcinoma or cervical cancer in situ, history of
             another malignancy, unless in remission for 5 years or more and judged of negligible
             potential of relapse;

          -  Known dihydropyrimidine dehydrogenase deficiency;

          -  Treatment with sorivudine or its chemically related analogues, such as brivudine,
             within 4 weeks prior to randomization;

          -  Evidence of any significant clinical disorder or concurrent illness or laboratory
             finding that, at the judgment of the Investigator, contra-indicate the inclusion of
             the patient in the study;

          -  Psychiatric disorders or altered mental status precluding understanding of the
             informed consent process and/or completion of the necessary study assessment and
             procedures;

          -  Unable to swallow tablets;

          -  Previous significant surgical resection of stomach or small bowel

          -  Patients requiring long-term oxygen therapy

          -  Known hypersensitivity to any excipients of oral vinorelbine, oral capecitabine and to
             fluoropyrimidine.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marina Cazzaniga, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ASST Monza</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Valter Torri, MD</last_name>
    <phone>+39 02 3901</phone>
    <phone_ext>4528</phone_ext>
    <email>valter.torri@marionegri.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>AOU Ospedali riuniti di Ancona</name>
      <address>
        <city>Torrette</city>
        <state>Ancona</state>
        <zip>60126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Rossana Berardi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASST Monza</name>
      <address>
        <city>Monza</city>
        <state>MB</state>
        <zip>20052</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Perea Gila</last_name>
      <phone>+39 093233203</phone>
    </contact>
    <investigator>
      <last_name>Marina Cazzaniga, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <state>PI</state>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Andrea Fontana, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria di Parma</name>
      <address>
        <city>Parma</city>
        <state>PR</state>
        <zip>43126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Antonio Musolino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile di Guastalla</name>
      <address>
        <city>Reggio Emilia</city>
        <state>RE</state>
        <zip>42016</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Filippo Giovanardi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Martini ASL Torino 1</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Anna Turletti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Tumori Giovanni Paolo II</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Vito Lorusso, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Tumori Giovanni Paolo II</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Francesco Giotta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASST Papa Giovanni XXIII</name>
      <address>
        <city>Bergamo</city>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Carlo Alberto Tondini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A. Ospedaliero universitaria di Bologna</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Claudio Zamagni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria Locale Brindisi</name>
      <address>
        <city>Brindisi</city>
        <zip>72100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Saverio Cinieri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASST - Cremona</name>
      <address>
        <city>Cremona</city>
        <zip>26100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Daniele Generali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. San Croce e Carle</name>
      <address>
        <city>Cuneo</city>
        <zip>12100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ornella Garrone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Vito Fazzi</name>
      <address>
        <city>Lecce</city>
        <zip>73100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Mariangela Ciccarese, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Marco Colleoni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico di Modena</name>
      <address>
        <city>Modena</city>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Laura Cortesi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico Paolo Giaccone</name>
      <address>
        <city>Palermo</city>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Maria Rosaria Valerio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Casa di Cura La Maddalena</name>
      <address>
        <city>Palermo</city>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Vittorio Gebbia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Felice Lotti</name>
      <address>
        <city>Pontedera</city>
        <zip>56025</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Giacomo Allegrini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Regina Elena</name>
      <address>
        <city>Roma</city>
        <zip>0144</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Patrizia Vici, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria di Sassari</name>
      <address>
        <city>Sassari</city>
        <zip>07100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Carlo Putzu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Portugues Oncologia de Coimbra</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-075</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Gabriela Sousa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHLN Hospital Santa Maria</name>
      <address>
        <city>Lisboa</city>
        <zip>1349-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Luis Costa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de S. Francisco Xavier</name>
      <address>
        <city>Lisboa</city>
        <zip>1449-005</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ana Martins, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Beatriz Angelo</name>
      <address>
        <city>Loures</city>
        <zip>2674-514</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Passos Coelho, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar Do Porto</name>
      <address>
        <city>Porto</city>
        <zip>4099-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Noemia Afonso, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar De Sao Joao EPE</name>
      <address>
        <city>Porto</city>
        <zip>4200</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Margarida Damasceno, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Portugues Oncologia de Porto</name>
      <address>
        <city>Porto</city>
        <zip>4200</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ines Pousa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Patricia Gomez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Salud</name>
      <address>
        <city>Toledo</city>
        <zip>45071</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Josè Ignacio Chacon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Raquel Andres, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Portugal</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2017</study_first_submitted>
  <study_first_submitted_qc>November 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2017</study_first_posted>
  <last_update_submitted>November 29, 2017</last_update_submitted>
  <last_update_submitted_qc>November 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TNBC</keyword>
  <keyword>metronomic chemotherapy</keyword>
  <keyword>vinorelbine</keyword>
  <keyword>capecitabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

